• Ibuprofen Synthesis Advances: Evidence from a 2021 Review

  2026-10-06

  Ha and Paek’s 2021 review maps recent advances in ibuprofen and naproxen synthesis, emphasizing practical, asymmetric, derivative-oriented, and continuous-flow approaches. Its main contribution is comparative: it shows how route design has evolved beyond classical preparation toward improved step economy, stereochemical control, scalability, and access to structurally refined NSAID candidates.

• NPC1/USP7/p53 Axis in Liver Cancer

  2026-10-06

  A 2026 Oncogene study identifies NPC1 as a multifunctional driver of hepatocellular carcinoma, connecting lysosomal cholesterol handling with USP7-dependent p53 destabilization. Its integrated clinical, cellular, animal, and mechanistic evidence supports NPC1 as a candidate regulator of HCC proliferation, while leaving important questions about patient-level therapeutic relevance.

• Bufuralol Hydrochloride: Evidence and Scope

  2026-10-05

  A source-grounded overview of what human iPSC-derived intestinal organoids can—and cannot—show about Bufuralol hydrochloride, β-adrenergic pharmacology, metabolism, transport and translational interpretation.

• Sodium Chloride B7288: Product Overview

  2026-10-05

  Sodium chloride (NaCl; CAS 7647-14-5; molecular weight 58.44) is an inorganic salt listed by APExBIO as a laboratory reagent for conceptual use in aqueous buffer preparation, ionic strength regulation, and osmotic balance. No matched paper evidence is available, so application-specific performance and suitability are not established.

• Decitabine in Cancer Epigenetics: Evidence and Limits

  2026-10-04

  This overview examines Decitabine (5-Aza-2'-deoxycytidine) as a DNA methyltransferase inhibitor in hematopoietic malignancy research and solid tumor epigenetic studies. It connects the compound’s conceptual role in tumor suppressor gene reactivation with recent findings on Helicobacter pylori-associated HNF4A silencing in gastric cancer, while distinguishing reported evidence from hypotheses and outlining key translational limitations.

• Hexamethonium Bromide in Autonomic Research

  2026-10-03

  Hexamethonium Bromide is studied as a ganglionic nicotinic-receptor antagonist in research on autonomic regulation. This overview examines its conceptual relevance to angiotensin II-induced hypertension, summarizes findings from a conscious-mouse study, and distinguishes evidence about ganglionic blockade from evidence specific to the compound.

• Palbociclib (PD0332991) in Tumor Assays

  2026-10-02

  Use Palbociclib as a mechanistic CDK4/6 probe, not simply as a viability reagent. This workflow connects cell-cycle arrest, apoptosis readouts, and patient-matched gastric cancer assembloids to reveal how stromal context can reshape drug response.

• Machine Learning for Senolytic Discovery

  2026-10-01

  The reference study shows that cost-effective machine-learning models trained on published, heterogeneous screening data can identify previously unrecognized senolytic candidates. Experimental validation of ginkgetin, periplocin, and oleandrin demonstrates a practical route from sparse literature data to cell-based discovery while highlighting the importance of senescence model and cell-type context.

• Angiotensin III: RAAS Workflows and Applications

  2026-10-01

  Angiotensin III supports controlled studies of aldosterone release, renin suppression, receptor signaling, and neuroendocrine pressor responses. Its emerging use in spike–receptor binding assays creates a carefully bounded bridge between cardiovascular research and exploratory viral biology.

• Nintedanib and ATRX: A Biomarker-Led View

  2026-09-30

  Nintedanib (BIBF 1120) is examined through an ATRX-informed glioma research framework, connecting triple angiokinase pharmacology with genotype-aware assay design. Learn how to distinguish pathway inhibition from biomarker-selective cytotoxicity in cancer and fibrosis studies.

• Wnt agonist 1: Assay Workflows for Wnt Biology

  2026-09-30

  Wnt agonist 1, also called BML-284, provides tunable canonical Wnt pathway activation for differentiation, developmental, and cancer-cell assays. This workflow connects pathway engagement to the Wnt/NR2F2/GPX4 chemoresistance model while separating established findings from practical experimental recommendations.

• Diclofenac in Human Intestinal Organoid Assays

  2026-09-29

  Diclofenac combines non-selective COX inhibition with a practical probe for linking epithelial exposure, prostaglandin biology, and intestinal pharmacokinetics. This workflow shows how to use it in hiPSC-derived organoid and monolayer systems while controlling solubility, vehicle effects, barrier transport, and assay interpretation.

• Amikacin Sulfate: From Exposure to Effect

  2026-09-29

  Amikacin Sulfate research is best interpreted through an exposure-to-effect framework that separates extracellular killing, intracellular activity, and granuloma localization. This article explains how dendritic-cell delivery, concentration-aware assays, and tissue-level readouts can improve experimental decisions in non-tuberculous mycobacterial models.

• SR 11302 AP-1 Inhibitor: Practical Workflows

  2026-09-28

  SR 11302 enables selective AP-1 pathway interrogation without activating RAR or RXR receptors, making it useful for cancer-cell and tumor-microenvironment studies. This guide translates published macrophage-polarization work into practical dosing, assay, controls, and troubleshooting strategies.

• CTP Solution for p21 mRNA-LNP Research

  2026-09-28

  See how CTP Solution can support the in vitro transcription workflow behind mRNA-LNP studies, from stock handling to RNA quality checks. A practical bridge to localized p21 mRNA research, with clear limits on what the bladder cancer study did—and did not—test about CTP.

8596 records 1/574 page Next 12345 下5页 Last page